- Algernon’s (CSE:AGN) subsidiary, Algernon NeuroScience, has completed dosing of its stroke and traumatic brain injury study
- The completion was successful of this Phase 1 clinical study of AP-188 (DMT)
- Algernon NeuroScience is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury
- Algernon Pharmaceuticals (AGN) opened trading at $0.25 per share
Algernon’s (CSE:AGN) subsidiary, Algernon NeuroScience, has completed Phase 1 dosing of its stroke and traumatic brain injury study.
The completion was successful of this third and final cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (N,N-Dimethyltryptamine or DMT). The purpose of the study was to identify the safety, tolerability, and pharmacokinetics of sub-psychedelic doses of DMT.
Algernon NeuroScience is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (TBI).
In pre-clinical studies, DMT increased brain derived neurotropic factor, which is believed to be a key mechanism involved in healing the brain after an injury. DMT is believed to activate pathways involved in forming neuronal connections and has been shown to increase the number of dendritic spines on cortical neurons.
The single escalating dose Phase 1 trial was conducted at the Centre for Human Drug Research in Leiden, Netherlands. Based on the success of the highest tested dose, the second part of the study, which will be scheduled to begin later.
Algernon Pharmaceuticals’ CEO, Christopher J. Moreau called Neuroplasticity’s role in healing the brain after an injury as one of the “most exciting areas of research going on globally” in the pursuit of a treatment for stroke and traumatic brain injury and stated that Algernon NeuroScience is at the forefront of this work.
“Now that we have established the safety of a single sub psychedelic dose of DMT, we are planning to accelerate our DMT Phase 2 studies accordingly, for both stroke and TBI.”
Algernon Pharmaceuticals Inc. (AGN) is a Canadian clinical-stage drug development company with active research programs for IPF, chronic cough, and chronic kidney disease. Its private subsidiary, Algernon NeuroScience, is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury. Recently, the Vancouver-based company received notice of allowance from the Japanese Patent Office for Repirinast and the treatment of chronic kidney disease. Click here to read more.
Algernon Pharmaceuticals (AGN) opened trading at $0.25 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
